The conformation of the title compound [systematic name: N-benzyl-2-(2-nitroimidazol-1-yl)acetamide], C12H12N4O3, can be described in terms of the relative orientation of three planar fragments, the imidazol group (A), benzyl group (B), and the ...
Bruno Dacunha-Marinho +4 more
doaj +4 more sources
Population pharmacokinetic-pharmacodynamic analysis of benznidazole monotherapy and combination therapy with fosravuconazole in chronic Chagas disease (BENDITA). [PDF]
IntroductionThe currently recommended 8-week daily benznidazole regimen for Chagas disease is poorly tolerated. While shorter benznidazole monotherapy and combination regimens have been explored, the pharmacokinetic/pharmacodynamic (PK/PD) relationship ...
Frauke Assmus +9 more
doaj +2 more sources
Treatment and seroconversion in a cohort of children suffering from recent chronic Chagas infection in Yoro, Honduras [PDF]
Between 1999-2002, Médécins Sans Frontières-Spain implemented a project seeking to determine the efficacy and safety of benznidazole in the treatment of recent chronic Chagas disease in a cohort of seropositive children in the Yoro Department, Honduras ...
Josep M Escribà +9 more
doaj +4 more sources
Antitrypanosomal therapy for Chagas disease: A single center experience with adverse drug reactions and strategies for enhancing treatment completion. [PDF]
Anti-trypanosomal therapy is generally recommended for individuals under age 50 with the indeterminate form of Chagas disease to prevent disease progression. However, benznidazole and nifurtimox are associated with adverse drug reactions.
Katherine Reifler +13 more
doaj +2 more sources
Pharmacokinetic-pharmacodynamic modeling of benznidazole and its antitrypanosomal activity in a murine model of chronic Chagas disease. [PDF]
BackgroundThere is an urgent need for improved treatments for Chagas disease, a neglected tropical infection caused by the protozoan parasite Trypanosoma cruzi.
Frauke Assmus +12 more
doaj +2 more sources
Population Pharmacokinetic Study of Benznidazole in Pediatric Chagas Disease Suggests Efficacy despite Lower Plasma Concentrations than in Adults [PDF]
Introduction:Chagas disease, caused by the parasite Trypanosoma cruzi, can lead to long term cardiac morbidity. Treatment of children with benznidazole is effective, but no pediatric pharmacokinetics data are available and clinical pharmacology ...
Altcheh, Jaime Marcelo +9 more
core +41 more sources
Clinical Progression of Cardiac Chronic Trypanosoma cruzi Infection in a Long-Term Prospective Cohort from Rural Colombia [PDF]
Chronic Trypanosoma cruzi infection remains a major cause of preventable cardiomyopathy in Latin America, yet prospective data from endemic rural populations after the interruption of domestic transmission are limited.
Mario J. Olivera +3 more
doaj +2 more sources
Dermatitis is the most common adverse event during treatment with benznidazole in chronic Chagas disease and is probably mediated by T cells. A set of molecules representative of the different type IV hypersensitivity reactions was evaluated in the ...
Melisa D. Castro Eiro +17 more
doaj +1 more source
Anti-parasitic effect of vitamin C alone and in combination with benznidazole against Trypanosoma cruzi. [PDF]
BACKGROUND:Drugs currently used for the treatment of Chagas' disease, nifurtimox and benznidazole, have a limited effectiveness and toxic side effects.
Vanesa Puente +4 more
doaj +1 more source
Nitazoxanide: A Drug Repositioning Compound with Potential Use in Chagas Disease in a Murine Model
Chagas disease (ChD), caused by Trypanosoma cruzi, is the most serious parasitosis in the western hemisphere. Benznidazole and nifurtimox, the only two trypanocidal drugs, are expensive, difficult to obtain, and have severe side effects. Nitazoxanide has
Minerva Arce-Fonseca +5 more
doaj +1 more source

